Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma (China)
CTR20200050Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200050.